Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AKTX with free AI briefings, catalyst countdowns, and dilution alerts.

AKTX · Akari Therapeutics Plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 4.7 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an S-1 registration filed Jan 23, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 months of cash or less, 51% sold new shares within three months and 73% were lower 60 trading days later (median -24%). How we know
$5.7M Cash on Hand
4.7mo Cash Runway
Follow AKTX by email Get an email when AKTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AKTX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nomacopan Thrombotic Microangiopathies Phase 3 · NCT04784455 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AKTX holds $5.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.7M/quarter from operations, an estimated runway of 4.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 85 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AKTX files for a raise →

👥 Who Owns AKTX

Insiders 0% Other 5%+ holders 27.8% Institutions (15 holders) 7.8% Public and other holders 64.4%
HolderTypeShares% of sharesAs of
Hoyoung Huh, M.D., Ph.D. 5%+ holder (13G) 18,199,697,667 11.68% 2026-03-02
Samir R. Patel 5%+ holder (13D) 9,725,215,000 6.24% 2026-03-02
Ray Prudo, M.D. 5%+ holder (13D) 8,391,326,467 5.39% 2026-03-02
White Lion Capital LLC 5%+ holder (13G) 7,001,638,477 4.50% 2026-08-07
Hoyoung Huh
Director, 10% owner · +7.94M options
Insider 140,805 0.00% 2026-08-18
Raymond Prudo-Chlebosz
Director · +2.08M options
Insider 76,861 0.00% 2026-08-18
Sandip I Patel
Director · +841,432 options
Insider 38,877 0.00% 2026-08-18
James R Neal
Director · +238,123 options
Insider 36,271 0.00% 2025-03-20
Kameel D. Farag
Interim CFO · +49,490 options
Insider 23,309 0.00% 2026-08-17
Robert B Bazemore
Director · +470,237 options
Insider 22,759 0.00% 2026-08-18
Abizer Gaslightwala
CEO, Director · +2.78M options
Insider 14,107 0.00% 2026-09-29
Samir Rashmikant Patel
Director · +1.73M options
Insider 12,102 0.00% 2026-08-18

Share count 155,758,529,533 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AKTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AKTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.